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Introduction
Platelets play a pivotal role in both normal hemostasis and
pathological thrombosis, especially in the arterial bed.
Atherosclerosis is the multifactorial result of endothe-
lial dysfunction, stimulation of inflammatory responses,
migration and proliferation of smooth muscle cells and
accumulation of monocyte-derived lipid-rich macrophages
to the injury site, and resultant formation of atheroscle-
rotic lesions.1–3 Ruptured plaques expose the subendothe-
lial matrix proteins and collagen to trigger a cascade of
events resulting in arterial vascular occlusion. Platelet acti-
vation and aggregation are integral in the pathogenesis of
atherothrombotic events characteristic of the acute coro-
nary syndromes (ACS) or due to mechanical disruption
of plaque by percutaneous coronary interventions (PCI).4
Accordingly, antiplatelet therapy has become an important
component of standard management in patients with ACS
and/or those who undergo PCI.
The field of platelet inhibition has evolved substantially
in the past decade with the initial establishment of dual
antiplatelet strategies (aspirin [ASA] and a thienopyridine)
in patients with ACS or who undergo PCI. Next, trial results
have modified how ASA, thienopyridines, and glycoprotein
(GP) IIb/IIIa antagonists are used in this setting. Unfortu-
nately, despite the use of standard antiplatelet approaches,
recurrent thrombotic events continue to occur, highlighting
the need to identify and bridge clinical gaps that remain in
this therapeutic area.
A panel of experts in interventional cardiology and platelet
inhibition was convened on November 17, 2006. The goal of
that meeting was to discuss the status of currently available
antiplatelet therapies and determine unmet clinical needs
that remain in the field. In this supplement, an evidence-
based review of the most important topics and clinical
needs identified by that panel is undertaken. The first
article features a review of landmark trials that establish
how antiplatelet therapies are currently used in patients
with ACS. This is followed by a review of the important
topic of platelet function testing and its current role. In the
third article, the problem of persistent platelet activation in
ACS and during the periprocedural and post-PCI periods is
introduced. In the concluding two articles, important issues
associated with the use of contemporary platelet inhibition
are explored, including the problem of hyporesponse and
variable response with certain antiplatelet strategies, optimal
loading and maintenance dosing with clopidogrel, the timing
of therapy prior to PCI, late stent thrombosis with the use
of drug eluting-stents, and the persistent problem of platelet
inhibitor underuse.
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